Arihant's Secur. (531017)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Book value per share is positive at ₹10.77, providing some tangible equity cushion.
• ROE and ROCE are positive at 2.68% and 1.70%, meaning the company is not currently eroding net worth.
• The stock is trading above its 52-week low of ₹14.21, showing some market support at lower levels.

Concerns

• Latest quarter sales and net profit are ₹0 Cr, suggesting business activity has stalled.
• Sales growth collapsed by 57.14% and profit growth by 78.85%, showing severe shrinkage.
• Piotroski F-score of 3/9 indicates weak financial health and operational quality.
• At ₹21.96 against book value of ₹10.77, there is no margin of safety, and dividend yield is zero.

AI Analysis

Turning to Arihant's Secur, I see a business that fails the first test I apply: can I understand its economics with confidence? The numbers are contradictory and troubling. The market price is ₹21.96, but book value is only ₹10.77, so I'd be paying more than twice book for a company with collapsing operations. Sales have fallen 57.14%, profit has fallen 78.85%, and the latest quarter shows zero sales and zero net profit. A P/E of 0.00 is not a sign of cheapness; it means earnings have nearly disappeared. ROE of 2.68% and ROCE of 1.70% are below what I could earn in a fixed deposit without taking business risk. The Piotroski F-score of 3 out of 9 reinforces my concern about financial health. There is no dividend, so I am relying entirely on price appreciation—and that is speculation, not investment. In Graham's language, behind this stock there must be an enterprise: with a ₹11 Cr market cap and a positive book value of ₹10.77 per share, there is some asset cushion, but it is not enough to provide a margin of safety at this price. Debt/equity is not available; that silence worries me, because hidden leverage can destroy equity quickly. Is this an asset play? No—asset plays require a stock below book value, not above. A turnaround? Possibly, but I do not invest in possible turnarounds; I wait until evidence of recovery appears in sales and earnings. This microcap fails my tests of durable advantage, predictable earnings, and financial strength. I would rather miss the opportunity than lose capital. If the business stabilizes, generates real sales, and the price approaches book value with a meaningfully higher margin of safety, I might look again. Until then, this is a pass.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer